ALRN: Aileron Therapeutics Net earnings per share for the last 12 months

Symbol and logo of brand Aileron Therapeutics Inc (ALRN)

Aileron Therapeutics (ALRN) operates in an environment of fierce competition against pharma behemoths with massive capital reserves. To carve out a niche, the company is implementing unique tissue protection mechanisms, as reflected by the TTM earnings per share trend on the GURU.Markets terminal chart, where -1.56 determines the current parameter status. This approach underscores the potential of the biopharmaceutical innovator as it develops targeted chemoprotection agents.

ALRN (Aileron Therapeutics) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/17/2026

Analytical breakdowns for Aileron Therapeutics

Basic company analysis:aileronrx.com - ALRN
Manufactured products of Aileron Therapeutics Inc

This indicator is calculated as the ratio of total net income to the total number of shares outstanding for the year. The metric determines the real monetary efficiency of each security by neutralizing the impact of equity dilution. For Aileron Therapeutics (ALRN), this calculation reflects the financial cost of developing the ALRN-101 drug and the expenses associated with clinical trials. Analyzing the earnings per share trend over the last 12 months allows for a real-time assessment of the business's fundamental stability. This chart's price action minimizes investment risks between quarterly reports.

Who Aileron Therapeutics competes with

GMAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year EXEL (Exelixis Corp)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) enliventherapeutics.com|Earnings per share for the last twelve months ORIC Pharmaceuticals, Inc. (ORIC)|RLAY (Relay Therapeutics, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics Inc)|Net earnings per share for the trailing year Tyra Bio|Verastem Oncology - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Therapeutics, Inc.|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|BPMC: Net earnings per share (EPS TTM)|GlycoMimetics Inc. - Earnings per share for the trailing year|SWTX (SpringWorks Therapeutics, Inc) - Net earnings per share (EPS TTM)